Contents of the Financial Statements

for the Period Ended 31 December 2025

Directors report
Profit and loss
Balance sheet
Additional notes
Balance sheet notes

Directors' report period ended 31 December 2025

The directors present their report with the financial statements of the company for the period ended 31 December 2025

Directors

The directors shown below have held office during the whole of the period from
1 January 2025 to 31 December 2025

JIANG HUA
DELIE BRUNO
ZHANG YEHONG

The above report has been prepared in accordance with the special provisions in part 15 of the Companies Act 2006

This report was approved by the board of directors on
20 July 2026

And signed on behalf of the board by:
Name: JIANG HUA
Status: Director

Profit And Loss Account

for the Period Ended 31 December 2025

	2025	2024
	£	£
Turnover:	22,443,270	16,131,619
Cost of sales:	( 8,139,194 )	( 6,187,511 )
Gross profit(or loss):	14,304,076	9,944,108
Distribution costs:	( 1,065,348 )	( 783,385 )
Administrative expenses:	( 12,697,148 )	( 8,735,969 )
Other operating income:	0	0
Operating profit(or loss):	541,580	424,754
Interest receivable and similar income:	3,543	0
Interest payable and similar charges:	( 516,875 )	( 340,850 )
Profit(or loss) before tax:	28,248	83,904
Tax:	( 6,428 )	( 23,954 )
Profit(or loss) for the financial year:	21,820	59,950

Balance sheet

As at 31 December 2025

	Notes	2025	2024
		£	£
Called up share capital not paid:		0	0
Fixed assets
Intangible assets:	3	13,311	9,203
Tangible assets:	4	0	1,197
Investments:	5	20,036	20,036
Total fixed assets:		33,347	30,436
Current assets
Stocks:	6	3,697,079	3,203,247
Debtors:	7	14,010,727	8,301,068
Cash at bank and in hand:		225,314	1,437,573
Investments:		0	0
Total current assets:		17,933,120	12,941,888
Prepayments and accrued income:		0	0
Creditors: amounts falling due within one year:	8	( 17,382,900 )	( 12,415,078 )
Net current assets (liabilities):		550,220	526,810
Total assets less current liabilities:		583,567	557,246
Creditors: amounts falling due after more than one year:		0	0
Provision for liabilities:		( 13,211 )	( 8,710 )
Accruals and deferred income:		0	0
Total net assets (liabilities):		570,356	548,536
Capital and reserves
Called up share capital:		1	1
Share premium account:		0	0
Other reserves:		0	0
Profit and loss account:		570,355	548,535
Total Shareholders' funds:		570,356	548,536

The notes form part of these financial statements

Balance sheet statements

For the year ending 31 December 2025 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The notes form part of these financial statements

Notes to the Financial Statements

for the Period Ended 31 December 2025

• 1. Accounting policies

  Basis of measurement and preparation

  These financial statements have been prepared in accordance with the provisions of Financial Reporting Standard 101

  Turnover policy

  The Company receives revenue for the supply of goods to external customers against orders received. Most contracts that the Company enters into relate to sales orders containing single performance obligations for the delivery of pharmaceutical products. Sales of pharmaceutical products are recognized when control of the goods is passed to the customer. The point at which control passes is determined by each customer arrangement, but generally occurs on delivery to the customer. Sales of pharmaceutical products represent net invoice value included fixed and variable consideration. Variable considerations arise on the sales of goods as a result of accrual for estimated future sales rebate. Revenue is not recognized in full until it is highly probable that a significant reversal in the amount of cumulative revenue recognized will not occur. The methodology and assumptions used to estimate rebate and returns are monitored and adjusted regularly in the light of contractual and legal obligations, historical trends, and projected market conditions. Once the uncertainty associated with rebate is resolved, revenue is adjusted accordingly. Value added tax and other sales taxes are excluded from revenue.

  Tangible fixed assets depreciation policy

  All items of property, plant and equipment are initially recorded at cost. Subsequent to recognition, property, plant and equipment are measured at cost less accumulated depreciation and any accumulated impairment losses. Depreciation is computed on a straight-line basis over the estimated useful lives of the assets as follows: Computers - 3 years Furniture and fittings - 3 years Office equipment - 3 to 10 years Leasehold improvement - 3 years The carrying values of property, plant and equipment are reviewed for impairment when events or changes in circumstances indicate that the carrying value may not be recoverable. The residual value, useful life and depreciation method are reviewed at each financial year-end, and adjusted prospectively, if appropriate. An item of property, plant and equipment is derecognised upon disposal or when no future economic benefits are expected from its use or disposal. Any gain or loss on derecognition of the asset is included in profit or loss in the year the asset is derecognised.

  Intangible fixed assets amortisation policy

  The Company leases corporate office space. Rental contracts are typically made for 60 days calculated from the date of lease and thereafter from month to month on a rolling basis. Lease terms are negotiated on an individual basis and contain a wide range of different terms and conditions. The lease agreements do not impose any covenants other than the security interests in the leased assets that are held by the lessor. Leased assets may not be used as security for borrowing purposes.

Notes to the Financial Statements

for the Period Ended 31 December 2025

• 2. Employees

  	2025	2024
  Average number of employees during the period	4	4